Patient Rating:

4.6 out of 5

44 Patient Ratings
14 Patient Comments

Martin C. Gregory, M.D., Ph.D.

Patient Rating:

4.6 out of 5

44 Patient Ratings
14 Patient Comments

Specialties

Languages

  • English
  • French

Clinical Details

Phone Number Clinical Office Address
(801) 585-6320
University Hospital
Kidney and Liver Clinic
50 N Medical Dr , Suite A100
Salt Lake City, UT 84132
Map

Bio

Martin Gregory, MD, PhD is a Clinical Professor of Medicine at the University of Utah School of Medicine. As a nephrologist, his clinical interests include general nephrology and hereditary renal diseases.

Dr. Gregory received his BM, BCh and DPhil Degrees (MD, PhD equivalents) from Oxford University. He received training in medicine and nephrology from the University of Otago, New Zealand, and Oxford University. He completed his residency at the University of London and at Oxford University, then fellowship in nephrology at Oxford University. He received further nephrology training at the University of Paris (VI). Dr. Gregory is board certified in Internal Medicine and Nephrology. In the past, Dr. Gregory served as Chief of Nephrology at Groote Schuur Hospital, Cape Town, South Africa and as Director of Dialysis Services, Bermuda Hospitals Board, Bermuda. He is currently a member of the Medical Advisory Board of the Alport Syndrome Foundation and a member of the Medical Advisory Board of the National Kidney Foundation of Utah and Idaho.

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor (Clinical)
Pediatrics - Adjunct Professor
Academic Divisions Nephrology
Pediatric Nephrology
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Nephrology)

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
4.5
My confidence in care provider
4.6
Time care provider spent with me
4.5
Care provider spoke using clear language
4.7
Care provider's effort to include me in decisions
4.5
Care provider's concern for questions & worries
4.6
Care provider's explanation of condition/problem
4.5
Wait time at clinic
4.4
Care provider's friendliness and courtesy
4.7

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

January 14, 2015

For one of the first times in my life, he made me feel like EVERY one of my concerns was legitmate and made me feel everything I had to say was important. He addressed each and every one of my concerns and took notes while I talked so as not to miss anything. Fantastic.

October 21, 2013

love the staff. Dr Fearday is the man!!

May 13, 2013

I am very happy with my doctor!

February 22, 2013

they are all awesome.

February 19, 2013

Dr. Fearday and Dr. Gregory spent a lot of time explaining my condition. I never felt rushed. I felt listened to.

February 11, 2013

I have no idea what half of what he said was. His accent is too strong. If he's smart enough to be a Dr he ought to be smart enough to do a better job of speaking english. The Dr. with the brit accent did just fine.

January 15, 2013

total experience was satisfying

January 14, 2013

They took the time to explain what was needed and WHY.

October 01, 2012

Would Have liked to spend a bit more time with the doctor(s) asking questions.

May 11, 2012

Dr Gregory has always been very thorough, helpful and kind.

May 03, 2012

I would recommend this doctor only if the scheduling problem could get worked out.

March 30, 2012

Dr. Gregory was very helpful and informative.

February 03, 2012

I saw a fellow, not Dr. Gregory. I do not have as much confidence in the fellow as Dr. Gregory, but he came in at the end to make sure she was on track. I know Dr. Gregory needs to cut back and some point, but he is irreplaceable as far as I'm concerned.

January 05, 2012

Excellent physician and a gentleman

Academic Profile

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor (Clinical)
Pediatrics - Adjunct Professor
Academic Divisions Nephrology
Pediatric Nephrology
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Nephrology)

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 581-6709 School of Medicine
Division of Nephrology & Hypertension
30 N 1900 E
Salt Lake City, UT 84132

Academic Bio

Martin Gregory, MD, PhD is a Clinical Professor of Medicine at the University of Utah School of Medicine. As a nephrologist, his research interests include the genetics of Alport syndrome and development of simple and inexpensive methods for dialysis in the developing world.

Dr. Gregory received his BM, BCh and DPhil Degrees (MD, PhD equivalents) from Oxford University. He received training in medicine and nephrology from the University of Otago, New Zealand, and Oxford University. He completed his residency at the University of London and at Oxford University, then fellowship in nephrology at Oxford University. He received further nephrology training at the University of Paris (VI). Dr. Gregory is board certified in Internal Medicine and Nephrology. In the past, Dr. Gregory served as Chief of Nephrology at Groote Schuur Hospital, Cape Town, South Africa and as Director of Dialysis Services, Bermuda Hospitals Board, Bermuda. He is currently a member of the Medical Advisory Board of the Alport Syndrome Foundation and a member of the Medical Advisory Board of the National Kidney Foundation of Utah and Idaho.

Education

Education History

Type School Degree
Residency Churchill Hospital
Neurology
Resident
Residency Hopital Necker
Nephrology
Resident
Doctoral Training University of Oxford
Ph.D.
Fellowship Radcliffe Infirmary
Nephrology
Fellow
Residency Hammersmith
Internal Medicine
Resident
Fellowship Churchill Hospital
Neph-Hypertension
Fellow
Graduate Training University of Oxford
Physiology
M.A.
Internship Radcliffe Infirmary
General Medicine/Surgery
Intern
Professional Medical University of Oxford
Medicine
M.D.
Undergraduate University of Oxford
B.A.
Undergraduate University of Otago
Premedical Sciences
B.Med.Sciences

Publications

Selected Provider Publications

Journal Article

  1. Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C (2013). Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol, 28(1), 5-11.
  2. Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, Schrier RW (2010). Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol, 21(5), 876-83.
  3. Gross O, Borza D-B, Anders H-J, Licht C, Weber M, Segerer S, Torra R, Gubler M-C, Heidet L, Harvey S, Cosgrove D, Lees G, Kashtan C, Gregory M, Savige J, Ding J, Thorner P, Abrahamson DR, Antignac C, Tryggvason K, Hudson B, Miner JH (2009). Stem cell therapy for Alport syndrome: the hope beyond the hype*. Nephrol Dial Transplant, 24, 731-734.
  4. Pont-Kingdon G, Sumner K, Gedge F, Miller C, Denison J, Gregory M, Lyon E (2009). Molecular testing for adult type Alport syndrome. BMC Nephrol, 10, 38.
  5. Gregory, MC (2009). Cost-Effective Dialysis for the Developing World. Ethn Dis, 19(Spring), S1 65-67.
  6. Zehnder AF, Adams JC, Santi PA, Kristiansen AG, Washarasindhu C, Mann S, Kalluri R, Gregory MC, Kashtan CE, Merchant SN (2005). Distribution of tiype IV collagen in the cochlea in Alport syndrome. Archives of Otolaryngology - Head & Neck Surgery, 131(11), 1007-13.
  7. Merchant SN, B urgess B J, Adams JC, Kashtan CE, Gregory MC, Santi PA, Colvin R Colns B, Nadol JB Jr (2004). Temporal bone histopathology in Alport syndrome. Laryngoscope, The, 114(9), 1609-18.
  8. Parr CJ, Miller FJ, Gregory MC, Yoon HC (2004). SIR 2004 Film panel case: Primary hyperoxaluria type I mimicking arterial vasculitis--a lethal disease. Journal of Vascular and Interventional Radiology, 15(9), 1017-20.
  9. Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, Denison JC, Gregory MC, White JG, Barker DF, Greinacher A, Epstein CJ, Glucksman MJ, Martignetti JA (2001). Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet, 69(5), 1033-45.
  10. Barker DF, Denison JC, Atkin CL, Gregory MC (2001). Efficient detection of Alport syndrome COL4A5 mutations with multiplex genomic PCR-SSCP. Am J Med Genet, 98(2), 148-60.
  11. Florell SR, Egan CA, Gregory MC, Zone JJ, Petersen MJ (2001). Eosinophilic fasciitis occurring four weeks after the onset of dialysis in a renal failure patient. J Cutan Med Surg, 5(1), 33-6.
  12. Haas LJ, Gregory MC (2000). Teaching behavior change skills to first-year medical students: a small group experiential approach. Educ Health (Abingdon), 13(3), 337-45.
  13. Sasaki S, Zhou B, Fan WW, Kim Y, Barker DF, Denison JC, Atkin CL, Gregory MC, Zhou J, Segal Y, Sado Y, Ninomiya Y, Michael AF, Kashtan CE (1998). Expression of mRNA for type IV collagen alpha1, alpha5 and alpha6 chains by cultured dermal fibroblasts from patients with X-linked Alport syndrome. Matrix Biol, 17(4), 279-91.
  14. Martin P, Heiskari N, Zhou J, Leinonen A, Tumelius T, Hertz JM, Barker D, Gregory M, Atkin C, Styrkarsdottir U, Neumann H, Springate J, Shows T, Pettersson E, Tryggvason K (1998). High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol, 9(12), 2291-301.
  15. Flanigan KM, Bromberg MB, Gregory M, Baringer JR, Jones CR, Nester TA, Klatt EC, Townsend JJ (1998). Calciphylaxis mimicking dermatomyositis: ischemic myopathy complicating renal failure. Neurology, 51(6), 1634-40.
  16. Barker DF, Denison JC, Atkin CL, Gregory MC (1997). Common ancestry of three Ashkenazi-American families with Alport syndrome and COL4A5 R1677Q. Hum Genet, 99(5), 681-4.
  17. Heiskari N, Zhang X, Zhou J, Leinonen Anu, Barker D, Gregory M, Atkin C, Netzer KO, Weber M, Reeders S, Grnhagen-Riska C, Neumann H, Trembath R, Tryggvason K (1996). Identification of 17 mutations in ten exons in the COL4A5 collagen gene, but no mutations found in four exons in COL4A6: a study of 250 patients with hematuria and suspected of having Alport syndrome. J Am Soc Nephrol, 7, 702-709.
  18. Barker DF, Pruchno CJ, Jiang X, Atkin CL, Stone EM, Denison JC, Fain PR, Gregory MC (1996). A mutation causing Alport syndrome with tardive hearing loss is common in the western United States. Am J Hum Genet, 58(6), 1157-65.
  19. Sprung RF, Cataldo RM, Gregory MC, Marks ML, Bull DA, Litwin SE (1996). Ruptured sinus of Valsalva aneurysm in a patient with autosomal dominant polycystic kidney disease. West J Med, 165(6), 379-82.
  20. Odell TW, Gregory MC (1995). Cost of hypertension treatment. J Gen Intern Med, 10(12), 686-8.
  21. Doyle AJ, Gregory MC, Terreros DA (1994). Percutaneous native renal biopsy: comparison of a 1.2-mm spring-driven system with a traditional 2-mm hand-driven system. Am J Kidney Dis, 23(4), 498-503.
  22. Cheung AK, DeVault GA, Gregory MC (1993). A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol, 31, 1884-1891.
  23. Zhou J, Gregory MC, Hertz JM, Barker DF, Atkin C, Spencer ES, Tryggvason K (1993). Mutations in the codon for a conserved arginine-1563 in the COL4A5 collagen gene in Alport syndrome. Kidney Int, 43(3), 722-9.
  24. Cheung AK, DeVault GA Jr, Gregory MC (1993). A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol, 3(12), 1884-91.
  25. Bichet DG, Arthus MF, Lonergan M, Hendy GN, Paradis AJ, Fujiwara TM, Morgan K, Gregory MC, Rosenthal W, Didwania A, et al (1993). X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis. J Clin Invest, 92(3), 1262-8.
  26. Bichet DG, Hendy GN, Lonergan M, Arthus M-F, Ligier S, Pausova Z, Kluge R, Zingg H, Saenger P, Oppenheimer E, Hirsch DJ, Gilgenkrantz S, Salles J-P, Oberl I, Mandel J-L, Gregory MC, Fujiwara M, Morgan K, Scriver CR (1992). X-linked nephrogenic diabetes insipidus: from the ship Hopewell to RFLP studies. Am J Hum Genet, 51, 1089-1092.
  27. Christensen AJ, Smith TW, Turner CW, Holman JM Jr, Gregory MC, Rich MA (1992). Family support, physical impairment, and adherence in hemodialysis: an investigation of main and buffering effects. J Behav Med, 15(4), 313-25.
  28. Christensen AJ, Turner CW, Smiths TW, Holman JM, Gregory MC (1991). Health locus of control and depression in chronic illness; moderating effects of treatment status and illness severity. Journal of Consulting and Clinical Psychology, 59, 419-424.
  29. Barker DF, Fain PR, Goldgar DE, Dietz-Bank JN, Turco AE, Kashtan CE, Gregory MC, Tryggvason K, Skolnick MH, Atkin CL (1991). High density genetic and physical mapping of DNA markers near the X-linked Alport syndrome locus: Definition and use of flanking polymorphic markers. Human Genetics, 88, 189-194.
  30. Leypoldt JK, Kablitz C, Gregory MC, Senekjian HO, Cheung AK (1991). Prescribing hemodialysis using a weekly urea balance model. Blood Purification, 9, 241-245.
  31. Giles TD, Weber M, Bartels DW, Gregory MC, Burris JF, Due D, Sirgo MA (1991). Evaluation of labetalol in elderly patients with essential hypertension. Journal of Clinical Hypertension, 31, 556-560.
  32. Christensen AJ, Smith TW, Turner CW, Holman JM Jr, Gregory MC (1990). Type of hemodialysis and preference for behavioral involvement: interactive effects on adherence in end-stage renal disease. Health Psychol, 9(2), 225-36.
  33. Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K (1990). Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science, 248(4960), 1224-7.
  34. Anderson CJ, Gregory MC, Groggel GC, Clegg DO 1989 (1989). Amyloidosis and Reiter's syndrome: report of a case and review of the literature. American Journal of Kidney Diseases, 14(4), 319-23.
  35. New Zealand Glomerulonephritis Study Group et al (1989). The New Zealand glomerulonephritis study: introductory report. Clinical Nephrology, 31(5), 239-246.
  36. Kashtan CE, Atkin CL, Gregory MC, Michael AF (1989). Identification of variant Alport phenotypes using an Alport-specific antibody probe. Kidney Int, 36(4), 669-74.
  37. Terreros DA, Gregory MC (1988). Metabolic Bone Disease in Patients Undergoing Chronic Dialysis. Am Soc Clinical Path. Check Sample Continuing Education Program. Clin Chem, CC88-7, 1-4.
  38. Gregory MC, Micklos T, Miller FJ, Servilla KS, Nelson EW (1988). Percutaneous dilation and stenting of ureteral stenosis in renal transplantation. Clinical Transplantation, 2, 107-109.
  39. Gregory MC, Hammond ME, Brewer ED (1988). Renal deposition of cytomegalovirus antigen in immunoglobulin-A nephropathy. Lancet, 1(8575-6), 11-4.
  40. Goodenough GK, Lutz LJ, Gregory MC (1988). Home-based renal dialysis. Am Fam Physician, 37(2), 203-14.
  41. Baker LR, Mallinson WJ, Gregory MC, Menzies EA, Cattell WR, Whitfield HN, Hendry WF, Wickham JE, Joekes AM (1987). Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br J Urol, 60(6), 497-503.
  42. Taylor A Jr, Akiya F, Gregory MC (1986). Failure to visualize acutely injured kidneys with technetium-99m DMSA does not preclude recoverable function. J Nucl Med, 27(3), 377-9.
  43. Cheung AK, Gregory MC (1985). Subclavian vein thrombosis in hemodialysis patients. Trans Am Soc Artif Intern Organs, 31, 131-5.
  44. Ekins BR, Rollins DE, Duffy DP, Gregory MC (1985). Standardized treatment of severe methanol poisoning with ethanol and hemodialysis. West J Med, 142(3), 337-40.
  45. Argyle C, Schumann GB, Genack L, Gregory M (1984). Identification of fungal casts in a patient with renal candidiasis. Hum Pathol, 15(5), 480-1.
  46. Gregory MC (1984). Acute renal failure after percutaneous cholangiography. Arch Intern Med, 144(6), 1288-9.
  47. Gregory MC, Schumann GB, Schumann JL, Argyle JC (1984). The clinical significance of candidal casts. Am J Kidney Dis, 4(2), 179-84.
  48. Smith JB, Ash KO, Gregory MC, Sprowell WL, Hentschel WM, Williams RR (1984). Hemodialysis does not affect erythrocyte sodium-lithium countertransport. Clin Chim Acta, 143(3), 275-9.
  49. Gregory MC, Duffy DP (1983). Toxic shock following staphylococcal peritonitis. Clin Nephrol, 20(2), 101-4.
  50. Gregory MC, Mansell MA (1983). Pregnancy and cystinuria. Lancet, 2(8360), 1158-60.
  51. Cassidy M, Gregory MC, Harley EH (1980). Primary overproduction of urate caused by a partial deficiency of hypoxanthine-guanine phosphoribosyl transferase. S Afr Med J, 57(23), 948-50.
  52. Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M (1979). Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab, 48(1), 50-3.
  53. Myers HS, Gregory M, Beighton P (1979). Renal failure in a 44-year-old female. Urol Radiol, 1(4), 251-3.
  54. Jacobs P, Wormald LA, Gregory MC (1979). Absorption of iron polymaltose and ferrous sulphate in rats and humans. A comparative study. S Afr Med J, 55(26), 1065-72.
  55. Pokroy N, Ress S, Gregory MC (1977). Clofibrate-induced complications in renal disease: a case report. S Afr Med J, 52(20), 806-8.
  56. Russo-Marie F, Gregory M, Ulmann A, Funck-Brentano JL (1976). [Role of sodium in the intestinal transport of calcium in idiopathic hypercalciuria]. Ann Med Interne (Paris), 127(2), 113-6.
  57. Gregory MC, Duval D, Meyer P (1976). Changes in cardiac and hepatic glucocorticoid receptors after adrenalectomy. Clin Sci Mol Med, 51(5), 487-93.
  58. Gregory MC, Hughes JT (1973). Intracranial reticulum cell sarcoma associated with immunoglobulin A deficiency. J Neurol Neurosurg Psychiatry, 36(5), 769-76.
  59. GREGORY MC, ROBINSON JR (1965). EFFECTS OF UREA UPON THE WATER AND IONIC CONTENT OF LIVER SLICES. J Physiol, 177, 122-32.

Review

  1. Gregory MC (2005). The clinical features of thin basement membrane nephropathy. [Review]. Semin Nephrol, 25(3), 140-5.
  2. Gregory MC (2004). Alport syndrome and thin basement membrane nephropathy: unraveling the tangled strands of type IV collagen. [Review]. Kidney Int, 65(3), 1109-10.
  3. Gregory MC, Terreros DA, Barker DF, Fain PN, Denison JC, Atkin CL (1996). Alport syndrome--clinical phenotypes, incidence, and pathology. [Review]. Contrib Nephrol, 117, 1-28.
  4. Barker DF, Atkin CL, Gregory MC, Fain PR (1996). Application of linked markers for genetic diagnosis of Alport syndrome. [Review]. Contrib Nephrol, 117, 29-45.
  5. Wester DC, Atkin CL, Gregory MC (1995). Alport syndrome: clinical update. [Review]. J Am Acad Audiol, 6(1), 73-9.
  6. Gregory MC, Shettigar UR, Kolff WJ (1984). Theoretical Value of Cascade plasmapheresis. [Review]. Plasma Ther, 5, 517-529.

Book Chapter

  1. Gregory, MC (2009). Alport's Syndrome and Related Disorders. In Greenberg, A (Eds.), Primer on Kidney Diseases (5th, pp. 358-363). Philadelphia: National Kidney Foundation/Saunders.
  2. Gregory MC, Shamshirsam A, Kamgar M, Bekhernia MR (2007). Alport's Syndrome, Fabry's Disease, and Nail-Patella Syndrome. In Schrier RW (Ed.), Diseases of the Kidney (8th Edition, pp. 540-569). Boston: Little Brown.
  3. Alverson DC, Saiki SM Jr, Caudell TP, Goldsmith T, Stevens S, Saland L, Colleran K, Brandt J, Danielson L, Cerilli L, Harris A, Gregory MC, Stewart R, Norenberg J, Shuster G, Panaoitis, Holten J 3rd, Vergera VM, Sherstyuk A, Kihmm K, Lui J, Wang KL (2006). Reification of Abstract Concepts to Improve Comprehension Using Interactive Virtual Environments and a Knowledge-based Design: A Renal Physiology Model. In Westwood JD, Haluck RS, Hoffman HM, Mogel GT, Phillips R, Rob RA, Vosburgh KG (Eds.), Medicine Meets Virtual Reality 14; Accelerating Change in Health Care: Next Medical Toolkit, Volume IV Studies in Health Technology and Informatics (pp. 13-18). Amsterdam, The Netherlands: IOS Press.
  4. Gregory MC (2005). Alport's Syndrome and Related Disorders. In Greenberg A (Ed.), A Primer on Kidney Diseases (4, pp. 363-367). New York: National Kidney Foundation.
  5. Gregory MD, Strong MB (2005). Manifestations and Pathophysiology. In Beringer P (Ed.), Remington's Pharmacuetical Sciences (21, pp. 1095-1141).
  6. Gregory MC (2001). Alport's Syndrome. In Schrier RW, Gottschalk CW (Eds.), Diseases of the Kidney (7th Ed, pp. 589-619). Little Brown, Boston.
  7. Gregory MC (2001). Alport's Syndrome and Related Disorders. In Greenberg A (Ed.), A Primer of Kidney Diseases (3rd Ed, pp. 308-312). National Kidney Foundation.
  8. Gregory MC (2001). Renal Function Tests. In Jones SL (Ed.), Clinical Laboratory Pearls (pp. 319-325). Philadelphia: Lippincott Williams and Wilkins.
  9. Gregory MC (2001). Urinalysis. In Jones SL (Ed.), Clinical Laboratory Pearls (pp. 326-336). Philadelphia: Lippincott Williams and Wilkins.
  10. Gregory MC, Tolman KG (2000). Diseases: Manifestations and Pathophysiology. In Gennaro AR et al (Ed.), Remington's Pharmaceutical Sciences (20th Ed, pp. 1053-1097).
  11. Gregory MC (1997). Alport's Syndrome and Related Disorders. In Greenberg A (Ed.), Primer on Kidney Diseases (2nd Ed, pp. 318-323). National Kidney Foundation.
  12. Gregory MC, Atkin CL (1997). Alport's Syndrome, Fabry's Disease, and Nail-Patella Syndrome. In Schrier RW, Gottschalk CW (Eds.), Diseases of the Kidney (6th Ed, pp. 561-590). Little Brown, Boston.
  13. Gregory MC, Atkin CL (1997). Hereditary nephropathies. In Kelley WM (Ed.), Textbook of Internal Medicine (3rd Ed, pp. 1018-1020). Philadelphia: Lippincott.
  14. Gregory MC (1997). Alport's Syndrome. In O'Kane P (Ed.), Companion to Kelley's Textbook of Internal Medicine (pp. 107-108). Philadelphia: Lippincott-Raven.
  15. Gregory MC, Terreros DA, Barker DF, Fain PR, Atkin CL (1996). Alport syndrome--clinical phenotypes, incidence, and pathology. In Tryggvason K (Ed.), Molecular Pathology and Genetics of Alport Syndrome (117, pp. 1-28). Contrib Nephrol Basel.
  16. Barker DF, Atkin CL, Fain PR, Gregory MC (1996). Clinical genetics and linkage markers in diagnosis of Alport Syndrome. In Tryggvason K (Ed.), Molecular Pathology and Genetics of Alport Syndrome (117, pp. 29-45). Contrib Nephrol Basel.
  17. Gregory MC (1994). Alport's Syndrome and Related Disorders. In Greenberg A (Ed.), A Primer of Nephrology (pp. 211-212). National Kidney Foundation.
  18. Gregory MC, Morgan SH (1994). Fabry's Disease. In Greenberg A (Ed.), A Primer of Nephrology (pp. 206-210). National Kidney Foundation.
  19. Gregory MC, Atkin CL (1993). Alport Syndrome. In Schrier RW, Gottschalk CW (Eds.), Diseases of the Kidney (pp. 571-591). Little Brown, Boston.
  20. Gregory MC (1992). Alport's Syndrome and related hereditary nephritides. In Andreucci VE, Fine LG (Eds.), International Yearbook of Nephrology (pp. 143-156).
  21. Gregory MC, Atkin CL (1992). Hereditary nephropathies. In Kelley WM (Ed.), Textbook of Internal Medicine (2nd Ed, pp. 736-738). Philadelphia: Lippincott.
  22. Gregory MC (1988). Artificial Kidney. In Webster JG (Ed.), Encyclopedia of Medical Devices and Instrumentation (3, pp. 1695-1712). New York: Wiley.
  23. Gregory MC, Border WA, Atkin CL (1988). Hereditary nephropathies. In Kelley WM (Ed.), Textbook of Internal Medicine (pp. 791-793). Philadelphia: Lippincott.
  24. Atkin CL, Gregory MC, Border WA (1988). Alport Syndrome. In Schrier RW, Gottschalk CW (Eds.), Diseases of the Kidney (4th Ed., pp. 617-641). Little Brown, Boston.
  25. Shettigar UR, Gregory MC, Kolff WJ (1987). Mathematical analysis of renal disease progression. In Andrade JD, Brophy JJ, Detmer DE, et al (Eds.), Artificial Organs (pp. 279-291). New York: VCH publishers.
  26. Fraser AK, Gregory MC, Rose GA, Samuell CT (1985). A study of factors affecting urinary citrate levels. In Schwille PO, Smith LH, Robertson WG, Wahlensieck W (Eds.), Urolithiasis and Related Clinical Research (pp. 249-252). New York: Plenum Press.
  27. Gregory MC (1978). Acid-base regulation. In Basic Medical Sciences (pp. 28-32). Cape Town: UCT Press.

Conference Proceedings

  1. Davies-Jones GAB, Gregory MC, Whitty CWM (1973). Permanent sequelae in the migraine attack. Background to Migraine, London: Heinemann, 5, 25-27.

Letter

  1. Solez K, Daugirdas J, Gregory MC, Frohnert PP, Bhowmik DM, Jha V, Cosyns JP (2001). Is "Chinese herbs nephropathy" a prejudicial term? [Letter to the editor]. Am J Kidney Dis, 38(5), 1141-2.
  2. Gregory MC (1985). Comparing US and other homicide rates [Letter to the editor]. West J Med, 143(3), 389-90.
  3. Kinniburgh DW, Ash KO, Gregory MC (1983). Should routine microscopic examination of urine be discontinued? [Letter to the editor]. Clin Chem, 29(1), 212-3.
  4. Gottheiner TI, Pokroy N, Gregory MC (1977). Herpes zoster with bladder involvement [Letter to the editor]. Lancet, 1(8010), 551.

Global Impact

Global Impact

Education History

Type School Degree Country
Residency Churchill Hospital
Neurology
Resident United Kingdom
Residency Hopital Necker
Nephrology
Resident France
Doctoral Training University of Oxford
Ph.D. United Kingdom
Fellowship Radcliffe Infirmary
Nephrology
Fellow United Kingdom
Residency Hammersmith
Internal Medicine
Resident United Kingdom
Fellowship Churchill Hospital
Neph-Hypertension
Fellow United Kingdom
Graduate Training University of Oxford
Physiology
M.A. United Kingdom
Internship Radcliffe Infirmary
General Medicine/Surgery
Intern United Kingdom
Professional Medical University of Oxford
Medicine
M.D. United Kingdom
Undergraduate University of Oxford
B.A. United Kingdom
Undergraduate University of Otago
Premedical Sciences
B.Med.Sciences New Zealand

Clinical Trials

Video & News